Famous Pro-Vaccine Doctor Suspects Pfizer’s Booster Shot Gave His Cancer Overgrowth: The Unhush Truth

for Suzanne Burdick, Ph.D. | The Defender

This article was originally published by The Defender – Children’s Health Defense news and opinion website.

Michel Goldman, MD, Ph.D., a professor of immunology and pharmacotherapy at the Free University of Brussels in Belgium, suspects that his third dose of Pfizer’s COVID-19 vaccine may have caused his cancer in excess.

Goldman, 67, is one of Europe’s best-known advocates of medical research and a lifelong promoter of vaccines.

But he told The Atlantic that he wants the COVID-19 vaccine discussion to be transparent, so he went public with his suspicion that the Pfizer booster vaccine he received on Sept. 22, 2021, may have induced rapid progression of his angioimmunoblastic T cell. lymphoma (AITL), a type of lymphoma diagnosed before receiving the booster vaccine.

After her diagnosis, Goldman said she rushed to get the booster shot, believing she would need it more than most people because once chemotherapy began, her immune system would be compromised.

But after getting the shot, Goldman’s follow-up CT scan showed something unexpected: In just a few days, her cancer had grown so fast that cancerous spots lit up all over her scan.

“It looked like someone had set off fireworks inside Michel’s body,” The Atlantic reported.

Goldman and his brother, Serge Goldman, also a scientist and head of nuclear medicine at the Free University of Brussels teaching hospital, suspected that Goldman’s COVID-19 booster vaccine may have triggered the rapid proliferation of the cancerous growth in your body.

The initial CT scan had been “a little disturbing,” Serge Goldman told The Atlantic, because it showed an asymmetric cluster of cancerous nodes around Goldman’s left armpit, where Michel’s first two doses of vaccine had been administered .

The CT scan taken after Michel’s third dose showed that the asymmetry of the cancer had reversed and was clustered in the right armpit, where he received the third shot.

The brothers knew it could be mere coincidence, but thought it important to investigate the possibility that the vaccine could be behind the clustering, because it could mean that other people with certain forms of cancer could be at risk from a vaccine against the COVID-19. making your cancer progress faster.

So on November 25, 2021, the brothers—who had written previous papers together—and other colleagues published a case report describing Michel Goldman’s experience and urging the scientific community to study the phenomenon to see if it occurred in patients diagnosed with AITL.

“Since nucleoside-modified mRNA vaccines strongly activate follicular helper T cells, it is important to explore the potential impact of approved SARS-CoV-2 mRNA vaccines on neoplasms affecting this cell type cells,” the authors wrote.

The brothers said the case study “suggests that vaccination with the [Pfizer-BioNTech] BNT162b2 mRNA vaccine could induce rapid progression of AITL.”

They noted, however, that it would be “premature” to extrapolate the findings from Michel Goldman’s case to other patients with the same type of cancer and that “dedicated studies are needed.”

Going public was “the right thing to do”

Michel Goldman’s case study has added to the scientific literature that aims to understand the relationships between mRNA vaccines and T helper cell function.

For example, previous researchers have noted that mRNA vaccines increase helper T cells, which may explain why Michel Goldman’s AILT went into overdrive after his third booster shot.

“Perhaps the shots gave his helper T cells such a jolt that they went berserk,” The Atlantic reported. “If they were prone to forming tumors, or if they were already cancerous, overstimulation could have made the problem even worse.”

Research involving body scans of some people who receive mRNA vaccines, including cancer patients, shows increased activity in lymph nodes near the armpit on the side where the vaccine was received.

In February 2018, a team of researchers from the Cancer Genetics Institute at Columbia University published a study that used mice with a pair of gene mutations, the same two mutations found in Michel Goldman’s tumor, which showed that mutations predispose T cells to go rogue.

The study also showed that when the mice were injected with sheep red blood cells, as an experimental replacement for the invading microbes, the mice developed the same subtype of lymphoma that Michel Goldman had.

Michel Goldman previously led a $2 billion European effort to accelerate research into new drugs and in December 2020, spoke out publicly in support of the safety of mRNA vaccines, the technology used in both Pfizer vaccines as Modern COVID-19.

At the time, he said the highest risk, especially for vulnerable people, is not getting vaccinated, and that his main concern about mRNA vaccination was that people might use the potential side effects as an argument against the vaccination

He currently directs the Institute of Interdisciplinary Innovation in Health, or I3h, a university center intended to help with drug design projects.

Michel Goldman has no regrets about going public with his case, even though he presented challenging evidence about the safety of mRNA vaccines for people like him.

“I’m still convinced it was the right thing to do,” he told The Atlantic.

He remains adamant that the COVID-19 vaccines are useful for the vast majority of people, but he’s not sure if he himself will get another booster dose.

“I don’t know what I’m going to do,” he said.

This article was originally published by The Defender — The Children’s Health Defense news and opinion website under a Creative Commons CC BY-NC-ND 4.0 license. Consider subscribing to The Defender or donating to Children’s Health Defense.

Source link

Leave a Reply

Your email address will not be published.